Authors: V. P. Shypulin, A. V. Neverovskyi, Bogomolets National Medical University Department of internal medicine № 1
Resume
The article describes the modern concepts of epidemiology, approaches to the diagnosis and treatment’s tactics of patients with metabolic syndrome (MS). It has been shown that using of UDCA (Choludexan) in the complex therapy of MS components is effective and appropriate. Rational use of UDCA (Choludexan) in the treatment of MS may reduce the risk of atherosclerosis, cardiovascular events and type 2 diabetes, prevents side effects of statins and the development and progression of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, as well as reduces the financial cost of the treatment of MS and its complications.
Key words: metabolic syndrome (MS), dyslipidemia, insulin resistance, ursodeoxycholic acid, Choludexan